Io­n­is widens eplon­ter­sen agree­ment with As­traZeneca; In­ozyme looks to get $60M in pub­lic of­fer­ing

As­traZeneca is pay­ing $20 mil­lion to Io­n­is to gain com­mer­cial­iza­tion rights in Latin Amer­i­ca for a drug wait­ing for the FDA’s sig­noff.


Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.